KDC-MN-203 – Kodiac biolabs

Plain-language summaryIntrigue 62 / 100

Paroxetine (Paxil) is an SSRI with the strongest grip on the serotonin pump in its entire class, but it also blocks acetylcholine receptors strongly enough to produce dry mouth, constipation, and the cognitive fog usually associated with older tricyclic antidepressants. GSK launched it in 1992. It has a notoriously rough discontinuation profile because its short half-life means the drug clears before the brain has time to adjust, producing the so-called brain zaps and flu-like symptoms patients describe when stopping abruptly. It is also a potent blocker of the CYP2D6 liver enzyme, which creates real interaction problems for people taking other medications. Approved for depression, panic, OCD, social anxiety, PTSD, and generalized anxiety. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Mature SSRI with highest SERT affinity in class; reference compound value preserves relevance but the frontier has moved

Look, paroxetine is a 1992 drug. That alone tells you most of what you need to know about where it sits in the research conversation. SmithKline Beecham brought it to market, GSK inherited it, and for about a decade it was one of the dominant SSRIs in clinical practice. The literature is enormous. Every major anxiety disorder, OCD, PTSD, PMDD, social phobia trial from the 1990s through mid-2000s has a paroxetine arm. Thats not novelty. Thats history.

Here’s the thing, though: the pharmacology is genuinely distinctive even if its not new. Paroxetine has the highest SERT affinity of any marketed SSRI by a substantial margin, Ki around 0.13 nM, which makes it the reference standard when labs want to characterize SERT binding in a new compound series. If you’re running a binding assay for a novel serotonergic scaffold and you need a ceiling comparator, paroxetine is your tool. That’s a real, if narrow, role. The muscarinic antagonism (Ki approximately 100 nM at M1) also makes it useful for disentangling serotonergic versus cholinergic contributions in mixed behavioral assays, which is not nothing.

The CYP2D6 story is arguably the most scientifically interesting thing about paroxetine in 2026. It’s both a substrate and a potent inhibitor of CYP2D6, which produces saturating nonlinear kinetics at higher doses. For pharmacogenomics work, paroxetine is one of the better-characterized probe drugs in the phenotyping literature. Poor metabolizers can reach exposures three to four times higher than extensive metabolizers at the same nominal dose. Thats a useful model system if you’re building out DDI or pharmacogenomics toolkits.

What we dont like: the discontinuation syndrome story, the weight gain, the sexual dysfunction profile, the anticholinergic burden compared to escitalopram or sertraline. As a therapeutic, paroxetine has been superseded on almost every quality-of-life dimension. The prescribing landscape reflects that. And as a research target, theres nothing novel to explore in its primary mechanism. SERT inhibition is a fully mapped territory. The muscarinic off-target is interesting historically but not an active research priority in 2026.

We think it scores near 45 because its evidence base is large and the human signal is clinically unambiguous, but novelty and mechanism drag it down hard. If your program specifically needs a high-affinity SERT reference, or a CYP2D6 pharmacogenomics probe, paroxetine earns its shelf space. Otherwise, you probably already have everything you need from the published literature and dont need to run new bench work.

Novelty: 18
Mechanism promise: 22
In-category differentiation: 38
Evidence quality: 82
Translational signal: 78
Research bench value: 55

Rationale Paroxetine scores low on novelty and mechanism because its pharmacology is textbook SSRI with well-characterized off-targets; it avoids a cap only because it retains genuine bench utility as the highest-affinity SERT reference standard and a pharmacogenomics model for CYP2D6 nonlinearity, which rescues the overall from the basement.

Selective serotonin reuptake inhibitor

A piperidine SSRI with the highest SERT affinity in the class and clinically significant muscarinic antagonism.

Abstract

Paroxetine ((3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; CAS 61869-08-7; molecular formula C19H20FNO3; molecular weight 329.36) is a phenylpiperidine SSRI developed at Ferrosan and licensed to SmithKline Beecham (now GSK), approved by the FDA in 1992 under the trade name Paxil. SERT affinity is the highest of any SSRI (Ki approximately 0.13 nM); off-target activity at muscarinic acetylcholine receptors (Ki approximately 100 nM) produces sedation and dry mouth at clinical doses, and weak NET inhibition contributes to noradrenergic effects at higher doses. Plasma half-life is approximately 21 hours with significant interpatient variability driven by CYP2D6 polymorphism (paroxetine is both a substrate and a potent inhibitor of CYP2D6, producing nonlinear pharmacokinetics at high doses). The compound exhibits the most pronounced discontinuation syndrome of the SSRI class, attributed to the relatively short half-life and muscarinic rebound on cessation. Used as a high-affinity SERT reference compound in receptor binding assays and as a comparator in OCD and anxiety disorder research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-203Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-203

Paroxetine

Abstract

Read the full monograph